★ Daily Intelligence Briefings (DIBs)⦁ Theme TrackerBiotechnology & HealthcareⓁ PharmaceuticalsMarkets Pfizer and Moderna Look to Put COVID Bust Behind Them, Add New Drug Development to Pipelines Several drugmakers whose sales boomed on COVID-19 vaccines and related products in 2021 and 2022 have now been embroiled in a hangover…McAlinden Research PartnersOctober 18, 2023
★ Daily Intelligence Briefings (DIBs)Biotechnology & HealthcareTechnology Robotic Surgical Procedures on the Rise as MedTech Firms Raise New Funds and Seek New FDA Approvals A new fundraising round by the UK's CMR Surgical, valuing the company at $3 billion, has foisted focus back onto…McAlinden Research PartnersSeptember 20, 2023
★ Daily Intelligence Briefings (DIBs)⦁ Theme TrackerBiotechnology & HealthcareⓁ PharmaceuticalsMarkets FTC Settles Suit Over Amgen-Horizon Deal, Potentially Averting Further Pharma M&A Hurdles The FTC's settlement with Amgen and Horizon has cleared the way for the two companies to complete a $27.8 billion…McAlinden Research PartnersSeptember 5, 2023
★ Daily Intelligence Briefings (DIBs)Biotechnology & HealthcareEconomics & Trade China Looks to Recharge Foreign Investment with Focus on Burgeoning Biopharma Business Some gauges indicate that foreign investment in China has sunken to 25-year lows recently. Beijing sees development of the country's biotechnology…McAlinden Research PartnersAugust 15, 2023
★ Daily Intelligence Briefings (DIBs)⦁ Theme TrackerBiotechnology & HealthcareⓁ PharmaceuticalsManufacturing & LogisticsMarkets Obesity Drugs’ Popularity Promises to Inject New Life Into Pharma Pipelines Summary: Ongoing shortages of popular obesity-fighting drugs from Novo Nordisk represent the surging popularity of medication-based intervention as treatment. Though…McAlinden Research PartnersJuly 25, 2023
★ Daily Intelligence Briefings (DIBs)Biotechnology & HealthcareMarketsPolitics & Policy Psychedelics Break New Ground in Clinical Trials, Research to be Bolstered by Key FDA Guidance New FDA guidance meant to steer clinical trials of psychedelic compounds will play a major role in the eventual approval…McAlinden Research PartnersJuly 12, 2023
★ Daily Intelligence Briefings (DIBs)⦁ Theme TrackerBiotechnology & HealthcareⓁ Gene EditingMarkets FDA Could Approve First CRISPR Treatment in US Before Year End, Marking New Territory for Gene Editing Tech CRISPR gene editing therapies took a big step toward commercialization in the United States last week, as the FDA laid…McAlinden Research PartnersJune 13, 2023
★ Daily Intelligence Briefings (DIBs)⦁ Theme TrackerBiotechnology & HealthcareⓁ Gene EditingMarkets More FDA Approvals Arise in Gene Editing Space, Renewed VC Rounds Begin to Ramp Up Shares of biotech firms focused on gene editing have been heating up this month, largely on the back of the…McAlinden Research PartnersMay 25, 2023
★ Daily Intelligence Briefings (DIBs)⦁ Theme TrackerBiotechnology & HealthcareⓁ PharmaceuticalsMarkets Johnson & Johnson Faces Patent Hurdles in Drug Business, Potentially Setting the Tone for Pharma Peers Johnson & Johnson's most recent earnings data showed revenues and earnings per share growing more robustly than analysts anticipated. However,…McAlinden Research PartnersApril 18, 2023
★ Daily Intelligence Briefings (DIBs)⦁ Theme TrackerBiotechnology & HealthcareFinanceⓁ PharmaceuticalsMarkets Pfizer’s M&A Strategy Sketches Roadmap for Pharma to Rebuild Pipelines, Overcome Patent Cliffs Pfizer's acquisition of Seagen, which is the largest biopharma deal since 2019, comes as products received in previous deals begin…McAlinden Research PartnersMarch 14, 2023